Global Biologics CDMO Market Report 2022: Analysis & Forecasts 2016-2026 by Type (Mammalian, Non-Mammalian), & Product Type (Biologics, Biosimilars) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Biologics CDMO Market (2022 Edition) – Analysis By Type (Mammalian, Non-Mammalian), Product Type (Biologics, Biosimilars), By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)” report has been added to ResearchAndMarkets.com’s offering.

Global Biologics CDMO Market was valued at USD 9.9 Billion in the year 2020.

Growth opportunities for the Biologics CDMO market are attributed to the growth of the geriatric population, rising technical advancements by the CDMO service providers, increasing trend of outsourcing the drug development processes in the world and increasing number of research and development activities by some of the key market players in the global platform.

In addition, increasing per capita disposable income, rising global healthcare expenditure along with the demand for new therapeutic drugs in the market is driving the Biologics CDMO market.

Moreover, with the rising prevalence of diseases in the world, it is expected that there will be more demand for new drugs which is likely to push the growth of Biologics CDMOs. Also, the rising number of pharmaceutical companies in the emerging economies, increasing demand for novel therapeutic applications along high demand for biologics are the major factors propelling the market growth.

Furthermore, the increased outsourcing trend by small and large pharmaceutical companies provides a promising opportunity for contract development and manufacturing organizations (CDMOs).

The outbreak of COVID-19 will influence the biologics CDMO market in the forecast period as well. This is due to the demand for vaccines and therapeutic antibodies which are expected to continue for several years.

In addition to the economic and social burden, the pandemic has prompted government bodies to increase funding for vaccine development on a global scale. With the ongoing crisis, there has been an immense burden on the healthcare sector worldwide and has impacted the discovery, research and development of many medicines pushing the growth of Biologics CDMO industry further.

The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

The companies analysed in the report include

• Lonza Group AG
• Samsung Biologics
• AbbVie Inc.
• WuXi Biologics Inc.
• Toyobo Co. Ltd.
• AGC Inc.
• Thermo Fisher Scientific Inc.
• ICON Plc
• Boehringer Ingelheim
• Fujifilm Diosynth Biotechnologies

Key Topics Covered:

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Global Biologics CDMO Market: Product Outlook

4. Global Biologics CDMO Market: Size and Forecast

4.1 Global Biologics CDMO Market Size, By Value, Year 2016-2026

5. Global Biologics CDMO Market Segmentation -By Type, By Product Type

5.1 Competitive Scenario of Global Biologics CDMO Market: By Type

5.1.1 Mammalian -Market Size and Forecast (2016-2026)

5.1.2 Non-mammalian (Microbial)-Market Size and Forecast (2016-2026)

5.2 Competitive Scenario of Global Biologics CDMO Market: By Product Type

5.2.1 Biologics-Market Size and Forecast (2016-2026)

5.2.2 Biosimilar -Market Size and Forecast (2016-2026)

6. Global Biologics CDMO Market: Regional Analysis

6.1 Competitive Scenario of Global Biologics CDMO Market: By Region

7. North America Biologics CDMO Market: An Analysis (2016-2026)

7.1North America Biologics CDMO Market: Size and Forecast (2016-2026)

7.2 North America Biologics CDMO Market -Prominent Companies

7.3 Market Segmentation by Type (Mammalian, Non-mammalian (Microbial))

7.4 Market Segmentation by Product Type (Biologics and Biosimilar)

7.5 North America Biologics CDMO Market: Country Analysis

7.6 Market Opportunity Chart of North America Biologics CDMO Market – By Country, By Value, 2026

7.7 Competitive Scenario of North America Biologics CDMO Market: By Country

7.8 United States Biologics CDMO Market: Size and Forecast (2016-2026), By Value

7.9 United States Biologics CDMO Market Segmentation – By Type, By Product Type (2016-2026)

7.10 Canada Biologics CDMO Market: Size and Forecast (2016-2026), By Value

7.11 Canada Biologics CDMO Market Segmentation – By Type, By Product Type (2016-2026)

Europe Biologics CDMO Market: An Analysis (2016-2026)

9. Asia Pacific Biologics CDMO Market: An Analysis (2016-2026)

10. Global Biologics CDMO Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Biologics CDMO Market -By Type, 2026

11.2 Market Attractiveness Chart of Global Biologics CDMO Market – By Product Type, 2026

11.3 Market Attractiveness Chart of Global Biologics CDMO Market – By Region, 2026

12. Competitive Landscape

12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers

12.2 Market Share Analysis

13. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/neg1yu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900